RhemaStem is a biotech company specializing in the research and development of effective innovative drugs in the field of colorectal cancer and other solid cancers. Headquartered in Monza, Italy, RhemaStem provides an advanced and a unique platform technology to address a critical shortcoming in existing methods of isolation and production of tumor and normal stem cells for drug discovery and development.
RhemaStem’s goal is to cure colorectal cancer and other solid cancers with our unique expertise and skills in the area of cancer and normal stem cells, an approach that we are promoting with great conviction. RhemaStem offers also consulting services in the area of solid cancer stem cells: Colon, Lungs, Breast, Prostrate, Ovary, Brain, Circulating blood cells and other cancers.
Below is a guest article from RhemaStem about the virtually unlimited expansion of clinically-relevant colon cancer tumorigenic cells. Enjoy!
Virtually unlimited expansion of clinically-relevant colon cancer tumorigenic cells
The concept that not all of the cells in a tumor posses true tumorigenic ability, down to the most critical capacity to possess typical stem cell-like features and to generate a true copy of the original neoplasia at the single cell level, is the central notion in the now broadening concept that many solid tumors may in fact, be established, perpetuated and recur after therapy because they contain a relatively rare sub-population of tumor-initiating cells.
These are most commonly called cancer stem cells or tumor-propagating cells, whose existence has been reported in colorectal human cancers, in which relatively rare subsets of CD133+ or CD133+/CD44+ have been isolated, that were shown to establish colorectal cancer upon heterotopic (subcutaneous or subcapsular, renal injection) transplantation in mice. Currently, some critical issues remain at hand regarding these COLON- CSCs (CCSCs).
Firstly, the actual self-renewing ability and, most important, expansion capacity of COLON-CSCs remains undefined. Cells have been reported to demonstrate exponential growth for one year ex vivo. While data supporting this concept are limited and the effective expansion rate of these cells remain undetermined.
Furthermore, there is no clear evidence that self-renewal and expansion of COLON-CSCs in this system effectively take place, as would be shown by clonogenic assays and serial sub-cloning. The significant expansion rate that we accomplished allows for the effective, routinely establishment of continuous lines of COLON-CSCs from human specimens.
RhemaStem has extensive, cogent cell growth kinetic,serial clonogenic analysis in vitro and in vivo serial transplantation experiments that distinctly demonstrate the virtually unlimited self-renewal capacity, significant expansion potential of COLON-CSCs from the human colorectal carcinomas.
In these lines, the very tumor-initiating cells that can reproduce the original colorectal cancer unfold their self-renewal potential, so that the very same COLON-CSCs are demonstrably perpetuated and amplified in number, as shown by their stable molecular, growth, differentiation and tumor-initiating characteristics, over virtually unlimited time.
This provides a system in which the main characteristics of the COLON-CSCs and bona-fide models of colorectal carcinomas can be stably and faithfully reproduced on a broad scale and over time.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.